Myeloproliferative Neoplasms News

The FDA removed the full clinical hold placed on studies that involve pacritinib, an oral tyrosine kinase inhibitor in development for the treatment of patients with myelofibrosis, according to the drug’s manufacturer.

The Fred Hutchinson Cancer Research Center announced the official opening of a first-of-its-kind clinic dedicated to providing cellular-based immunotherapies for patients with cancer.

ASH selected 20 junior medical educators to participate in its ASH Medical Educators Institute.

ASH selected 20 junior medical educators to participate in its ASH Medical Educators Institute.

SAN DIEGO — Aaron T. Gerds, MD, spoke with HemOnc Today about results of the PERSIST-2 trial, presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — The investigational agent BLU-285 appeared active and safe in patients with advanced systemic mastocytosis, according to study results presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — Aaron T. Gerds, MD, assistant professor of medicine at Cleveland Clinic Taussig Cancer Center, discusses the interim results of a trial that compared first-line PEGylated interferon alpha-2a with hydroxyurea for patients with myeloproliferative neoplasms, conducted by the Myeloproliferative Disorders Research Consortium and presented at the ASH Annual Meeting and Exposition.

Hematopoietic stem cell transplantation survivors experience significantly greater rates of hospitalization and mortality from all causes years after their transplants than cancer survivors who did not undergo HSCT, according to a comparative study published in Journal of Clinical Oncology.

SAN DIEGO — Pacritinib more effectively led to spleen volume reduction than best available therapy in patients with myelofibrosis and platelet counts less than 100,000/µl, including those who had previously received a JAK2 inhibitor, according to results of the PERSIST-2 trial presented during the late-breaking abstract session of the ASH Annual Meeting and Exposition.

SAN DIEGO — Patients with higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia responded favorably to guadecitabine, according to findings presented at the ASH Annual Meeting and Exposition.